ACUTAAS®
You and us: chemistry's apex

ACUTAAS CHEMICALS LIMITED
(Formerly known as Ami Organics Limited)
CIN No. : L24100GJ2007PLC051093

July 24, 2026

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot no. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

NSE Symbol: ACUTAAS

Subject: Unaudited Standalone & Consolidated Financial Results for the First Quarter ended June 30, 2026

We would like to inform that the Board of Directors at its meeting held on July 24, 2026 inter alia, considered and approved the Unaudited Standalone and consolidated Financial Results for the first quarter ended June 30, 2026 as recommended by the Audit Committee.

The Board also took note of the 'Limited Review Report' issued by the Company's Statutory Auditors, M/s. Maheshwari & Co. Chartered Accountants. We enclose herewith copy of the Unaudited Financial Results (Standalone and Consolidated) for the first quarter ended June 30, 2026 and the said Limited Review Report.

As required under Regulation 47 (1) (b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the extract of the Financial Results will be published in the newspapers in the format prescribed by SEBI. The Financial Results will also be available on the Company's website at www.acutaas.com

Kindly take above as compliance of Regulation 33 and 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.00 a.m. and concluded at 12.15 p.m.

Thanking you,
Yours faithfully,

For, ACUTAAS CHEMICALS LIMITED

Ekta Kumari

Ekta Kumari Srivastava
Company Secretary & Compliance Officer
Encl: As above

ACUTAAS CHEMICALS LIMITED

Independent Auditor's Review Report on Review of Interim Consolidated Financial Results

To The Board of Directors
Acutaas Chemicals Limited (formerly known as Ami Organics Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Acutaas Chemicals Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its associate and joint venture for the quarter ended June 30, 2026 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulation . Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
   a. Holding Company: Acutaas Chemicals Limited
   b. Subsidiary Company: Acutaas Chemicals Electrolytes Private Limited
   c. Wholly owned Subsidiary Company: Acutaas Advance Material Limited
   d. Subsidiary: Baba Fine Chemicals (Partnership Firm)
   e. Joint Venture: Ami Onco-Theronostics, LLC
   f. Step down subsidiary: Enchem Ami Organics Private Limited
   g. Step down subsidiary: Indichem Inc.

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard ("Ind AS 34") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

Kriti Bansal
(Partner)
Membership No.: 459589

Place: Mumbai
Date: July 24, 2026

UDIN: 26459589RNGRBT7869

®

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Unaudited Financial Results for the Quarter June 30, 2026

(₹ in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
	Unaudited	Unaudited	Unaudited	Audited
Income				
Revenue from operations	32,967.48	43,275.05	20,723.72	133,936.68
Other income	180.13	1,111.10	1,593.77	4,158.52
Total income	**33,147.61**	**44,386.15**	**22,317.49**	**138,095.20**
Expenses				
Cost of materials consumed	16,577.06	18,368.60	10,406.01	59,495.95
Changes in inventories of finished goods, stock-in -trade and work-in-progress	(2,701.29)	(1,924.52)	(716.98)	(2,900.34)
Employee benefits expense	3,956.70	3,328.86	2,507.33	11,757.19
Finance costs	114.10	118.97	63.85	326.81
Depreciation and amortization expense	982.13	963.03	813.08	3,598.76
Other expenses	3,827.90	5,151.04	3,436.63	17,544.26
Total expenses	**22,756.60**	**26,005.98**	**16,509.92**	**89,822.63**
Profit before exceptional items and tax	**10,391.01**	**18,380.17**	**5,807.57**	**48,272.57**
Exceptional Items	-	-	-	-
Profit before tax	**10,391.01**	**18,380.17**	**5,807.57**	**48,272.57**
Tax expense				
Current tax	2,725.60	4,883.13	1,272.82	11,719.75
Deferred tax	166.14	68.67	133.70	915.89
Total tax expense	**2,891.74**	**4,951.80**	**1,406.52**	**12,635.64**
Profit for the period	**7,499.27**	**13,428.37**	**4,401.05**	**35,636.93**
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Remeasurement of defined employee benefit plans	(8.76)	28.78	(4.37)	(35.02)
Tax impact on items that will not be reclassified to profit or loss	2.12	(8.01)	0.92	8.46
Items that will be reclassified to profit or loss				
Exchange differences on translation of financial statements of foreign entity	(209.36)	(336.67)	-	(295.88)
Other comprehensive income	**(216.00)**	**(315.89)**	**(3.45)**	**(322.44)**
Total comprehensive income for the period	**7,283.27**	**13,112.48**	**4,397.60**	**35,314.49**
Profit attributable to				
Owners of the company	7,426.01	13,176.08	4,429.34	35,625.53
Non - controlling interest	73.26	252.29	(28.29)	11.40
Other comprehensive income attributable to				
Owners of the company	(217.05)	(316.22)	(3.12)	(323.49)
Non - controlling interest	1.05	0.32	(0.33)	1.05
Paid up equity share capital (face value of ₹ 5 each)	4,093.56	4,093.56	4,093.45	4,093.56
Equity shares of face value Rs. 5/- each				
Other equity				161,262.54
Earnings per equity share of ₹ 5 each (not annualised, excluding year end)				
Basic (₹)	9.07	16.09	5.41	43.51
Diluted (₹)	9.04	16.04	5.41	43.37

For Acutaas Chemicals Limited

Date: July 24, 2026

Place: Surat

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

ACUTAAS CHEMICALS LIMITED

Nareshkumar Ramjibhai Patel

Chairman & Managing Director

DIN: 00906232

Notes to the Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

1. The above unaudited consolidated financial results for the quarter ended June 30, 2026, which includes the financial information of Acutaas Chemicals Limited (Formerly known as Ami Organics Limited) ("the Company"), its subsidiary entities namely, Acutaas Chemicals Electrolytes Private Limited (formerly known as Ami Organics Electrolytes Private Limited), Acutaas Advance Material Limited (formerly known as Baba Advance Materials Limited) and Baba Fine Chemicals (collectively "the group"), its step down subsidiary entities namely, Enchem Ami Organics Private Limited and Indichem Inc. and its joint venture namely, Ami Onco-Theronostics LLC, were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 24, 2026. The Statutory Auditors of the Company have carried out a limited review of the consolidated unaudited financial results for the quarter ended on June 30, 2026. Their limited review report does not have any modification.

2. The above unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

4. During the quarter, pursuant to a preferential issue of equity shares on a partly paid-up basis by Acutaas Chemicals Electrolytes Private Limited ("ACEPL"), a subsidiary of the Company, to A.R.Z Pharma Ltd., the Company's shareholding in ACEPL stood diluted from 100% to 90% with effect from May 19, 2026. Consequently, ACEPL ceased to be a wholly owned subsidiary and continues to remain a subsidiary of the Company. The aforesaid dilution has not resulted in any change in the Company's control over ACEPL.

5. During the quarter, the Central Goods & Service Tax and Central Excise (CGST & CE), Anti-Evasion Department, initiated inspection/search proceedings at the Company's registered office and manufacturing facility in Surat, Gujarat on June 22, 2026 and concluded the inspection/search on June 23, 2026. Based on the information available as on the date of approval of these financial results, the management does not expect any material impact on the financial position, results of operations or cash flows of the Company.

6. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.

7. The figures for the quarter ended March 31, 2026, are balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.

8. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.

For and behalf of Board of Directors of
Acutaas Chemicals Limited
(Formerly known as Ami Organics Limited)

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

ACUTAAS CHEMICALS LIMITED

Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

Date: July 24, 2026
Place: Surat

Independent Auditor's Review Report on Review of Interim Standalone Financial Results

To The Board of Directors,
Acutaas Chemicals Limited (formerly known as Ami Organics Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Acutaas Chemicals Limited ('hereinafter referred to as "the Company") for the quarter ended June 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listed Regulations")

2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ("Ind AS 34") and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard ("Ind AS 34") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

Kriti Bansal
Partner
Membership No.: 459589
UDIN: 26459589RGYXSM1572

Place: Mumbai
Date: July 24, 2026

®

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India
Tel: +91 72279 77744; +91 75730 15366
Website: www.acutaas.com Email: cs@acutaas.com

Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026

(₹ in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
	Unaudited	Unaudited	Unaudited	Audited
Income				
Revenue from operations	32,240.92	42,177.23	20,597.09	132,379.22
Other income	447.60	1,454.59	1,602.01	4,587.83
Total Income	**32,688.52**	**43,631.82**	**22,199.10**	**136,967.05**
Expenses				
Cost of materials consumed	16,397.25	18,327.47	10,317.71	59,249.92
Changes in inventories of finished goods, stock-in -trade and work-in-progress	(2,433.67)	(2,063.77)	(654.23)	(3,068.80)
Employee benefits expense	3,740.16	3,133.43	2,440.25	11,134.98
Finance costs	111.79	107.19	61.96	307.72
Depreciation and amortization expense	902.02	883.00	746.21	3,303.22
Other expenses	3,569.47	4,658.41	3,394.50	16,762.62
Total expenses	**22,287.02**	**25,045.73**	**16,306.40**	**87,689.66**
Profit/(loss) before exceptional items and tax	**10,401.50**	**18,586.09**	**5,892.70**	**49,277.39**
Exceptional items	-		-	-
Profit/(loss) before tax	**10,401.50**	**18,586.09**	**5,892.70**	**49,277.39**
Tax expense				
Current tax	2,553.25	4,705.39	1,272.82	11,549.05
Deferred tax	258.68	173.58	155.26	1,110.89
Total tax expense	**2,811.93**	**4,878.97**	**1,428.08**	**12,659.94**
Profit for the period	**7,589.57**	**13,707.12**	**4,464.62**	**36,617.45**
Other comprehensive income (OCI)				
Items that will not be reclassified to profit or loss				
Remeasurement of defined employee benefit plans	(9.65)	26.83	(3.65)	(38.60)
Tax impact on items that will not be reclassified to profit or loss	2.43	(6.76)	0.92	9.71
Total other comprehensive income (net of tax)	**(7.22)**	**20.07**	**(2.73)**	**(28.89)**
Total comprehensive income for the period	**7,582.35**	**13,727.19**	**4,461.89**	**36,588.56**
Details of equity share capital				
Equity shares of face value Rs. 5/- each	4,093.56	4,093.56	4,093.45	4,093.56
Other equity				162,745.21
Earnings per equity share of ₹ 5/- each (not annualised, excluding year end)				
Basic (₹)	9.27	16.74	5.45	44.73
Diluted (₹)	9.24	16.64	5.45	44.58

Date: July 24, 2026
Place: Surat

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

ACUTAAS CHEMICALS LIMITED

For Acutaas Chemicals Limited

Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

Notes to the Unaudited Standalone Financial Results for the quarter ended June 30, 2026

1. The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 24, 2026. The Statutory Auditors of the Company have carried out a limited review of the standalone unaudited financial results for the quarter ended June 30, 2026. Their limited review report does not have any modification.

2. The above unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

4. During the quarter, the Central Goods & Service Tax and Central Excise (CGST & CE), Anti-Evasion Department, initiated inspection/search proceedings at the Company's registered office and manufacturing facility in Surat, Gujarat on June 22, 2026 and concluded the inspection/search on June 23, 2026. Based on the information available as on the date of approval of these financial results, the management does not expect any material impact on the financial position, results of operations or cash flows of the Company.

5. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.

6. The figures for the quarter ended March 31, 2026, are balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.

7. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.

For and behalf of Board of Directors of
Acutaas Chemicals Limited
(Formerly known as Ami Organics Limited)

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

ACUTAAS CHEMICALS LIMITED

Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

Date: July 24, 2026
Place: Surat